1. Home
  2. GCBC vs CABA Comparison

GCBC vs CABA Comparison

Compare GCBC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greene County Bancorp Inc.

GCBC

Greene County Bancorp Inc.

HOLD

Current Price

$22.30

Market Cap

374.8M

Sector

Finance

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$3.17

Market Cap

319.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCBC
CABA
Founded
1889
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
374.8M
319.6M
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
GCBC
CABA
Price
$22.30
$3.17
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$14.57
AVG Volume (30 Days)
8.6K
2.8M
Earning Date
04-22-2026
01-01-0001
Dividend Yield
1.80%
N/A
EPS Growth
26.21
N/A
EPS
1.13
N/A
Revenue
$4,117,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.66
N/A
Revenue Growth
11.06
N/A
52 Week Low
$20.00
$0.99
52 Week High
$26.21
$3.78

Technical Indicators

Market Signals
Indicator
GCBC
CABA
Relative Strength Index (RSI) 43.63 56.08
Support Level $21.39 $2.11
Resistance Level $23.48 $3.34
Average True Range (ATR) 0.83 0.30
MACD -0.10 -0.01
Stochastic Oscillator 19.70 43.07

Price Performance

Historical Comparison
GCBC
CABA

About GCBC Greene County Bancorp Inc.

Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: